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THE MEDICARE PART D PRESCRIPTION DRUG
BENEFIT: WHO WINS AND WHO LOSES?
Erich Andreas Drotleff*
INTRODUCTION
In December 2003, Congress amended Title XVIII of the Social
Security Act (Medicare) by adding a voluntary prescription drug
benefit, titled Medicare Part D.1  The Medicare Part D
prescription drug program took effect on January 1, 2006, and
began providing some form of prescription drug coverage for
millions of America's seniors, who historically had no such
coverage under traditional Medicare Parts A and B.2 Members
of Congress argued that Medicare's traditional inpatient
coverage did not effectively control healthcare expenses, and
Medicare failed to effectively manage chronic conditions with
outpatient prescription medications.3
The first part of this article provides a brief historical
overview of the original Medicare program including program
changes to the present. The article then focuses on the Medicare
prescription drug program; specifically, the drug program's
*Erich Drotleff holds a J.D. from California Western School of Law, a
B.S. in Animal Physiology from the University of California, San Diego,
and a M.S. in Public Health from San Diego State University. Prior to
law school, he worked as a contracts manager for several large
California health plans.
1. Medicare Prescription Drug, Improvement, and Modernization Act of 2003,
Pub. L. No. 108-173, 117 Stat. 2066 (codified at 42 U.S.C.A. §§ 1395w-101 to -152
(Westlaw current through October 3, 2006)).
2. Edward F. McArdle, 2003-2004 Survey of New York Law: Health Law, 55
SYRACUSE L. REV. 1107, 1111-12 (2005).
3. LAWRENCE A. FROLIK & ALISON MCCHRYSTAL BARNES, ELDER LAW CASES
AND MATERIALS 233 (3d ed. 2003).
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congressional history and politics, leading to the legislation's
passage. Next, the article examines those interest groups
benefiting from the drug program and analyzes whether the
Medicare beneficiaries truly benefit. The article concludes with
recent findings on implementation, as well as recommendations
for different approaches to providing prescription drugs for
Medicare beneficiaries.
HISTORY OF MEDICARE
Congress enacted Medicare in 1965 to address the healthcare
needs of people over sixty-five, a group frequently without the
means to pay for medical services.4 The program was designed
to provide a limited and basic healthcare benefit.' All
beneficiaries pay the same for hospital and physician services,
regardless of their income level or "ability to pay." 6 Medicare
provides healthcare coverage to virtually all seniors sixty-five
and older, accounting for approximately 43.5 million Americans
who receive Medicare benefits.'
For the first thirty-two years of its existence, Medicare
remained consistent with its original benefit design. Medicare
Part A provided "inpatient hospitalization and related benefits
funded by an employee tax at no cost to the patient."8 Part B
provided physician and some outpatient services for
beneficiaries who elected such coverage and paid a monthly
premium.9
The Balanced Budget Act of 1997 (BBA)10 created a new
4. McArdle, supra note 2, at 1111.
5. Id.
6. Id.
7. HENRY J. KAISER FAMILY FOUNDATION, MEDICARE BENEFICIARIES WITH
CREDITABLE PRESCRIPTION DRUG COVERAGE BY TYPE (June 11, 2006),
http://www.statehealthfacts.org/cgibin/healthfacts.cgi?action=compare&category=
Medicare&subcategory-Medicare+Drug+Benefit&topic=Medicare+Rx+Drug+Cover
age (last visited Nov. 4, 2006).
8. McArdle, supra note 2, at 1111.
9. Id. at 1111-12.
10. Pub. L. No. 105-33, 111 Stat. 251 (codified as amended at 42 U.S.C.A. §§
1395w-21 to -29) (Westlaw current through Oct. 3, 2006).
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Medicare program called Part C, which was designed to offer a
managed care option to Medicare recipients nationwide in
addition to the traditional Medicare Parts A and B fee-for-service
components." Called Medicare + Choice under Part C, the BBA
provided additional funding and revenue to Medicare Health
Maintenance Organizations (HMOs) in order to incentivize and
induce managed care plans to actively market and enroll
Medicare Part A and B recipients into Part C.12
These Medicare Part C HMOs contract with the federal
government and provide Medicare beneficiaries with hospital
and medical services traditionally covered under Medicare Parts
A and B.'3 Additionally, they usually offer a pharmacy benefit
in addition to the traditional Part A and B benefits, often without
the beneficiary incurring any premiums, deductibles, or
coinsurance.14 At that time, only Medicare HMOs offered an
outpatient prescription drug benefit since outpatient
prescription medications were not covered under Medicare Parts
A or B.'s
In the early 2000s, Congress, under pressure from seniors
and public advocacy groups, decided to add a prescription drug
benefit to traditional Medicare Parts A and B and to overhaul
Medicare Part C to "reflect a market-driven approach." 6 As a
result of increased drug costs and a movement away from
hospital-based medical care to an outpatient and maintenance
drug therapy approach to controlling chronic health conditions,
lawmakers drafted a drug program that would be consistent
with Medicare's universal coverage.'7
In December 2003, Congress passed, and President George
W. Bush signed, the Medicare Prescription Drug Improvement
11. McArdle, supra note 2, at 1112.
12. FROLIK & BARNES, supra note 3, at 232.
13. Id. at 227.
14. Id.
15. Id. at 233.
16. McArdle, supra note 2, at 1111.
17. Id. at 1112.
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and Modernization Act of 2003.18 Commonly referred to as the
MMA, the Act's addition of a prescription drug benefit may
represent "the most ambitious change in the history of the
Medicare program." 9
NUTS AND BOLTS OF THE MMA
The legislation creates the drug benefit; it makes significant
changes to Part B finance and authorizes other market oriented
initiatives in Medicare.
MEDICARE PART D PRESCRIPTION DRUG PROGRAM
The MMA provides a voluntary drug benefit under
Medicare Part D for beneficiaries enrolled in Medicare Parts A
and B and is administered through a prescription drug plan.20
Drug benefits are provided through either stand-alone
prescription drug plans (PDPs) for beneficiaries who elect to
remain with traditional Medicare Parts A and B, or through
Medicare Advantage (MA) plans that have incorporated
Medicare Parts A and B benefits.21
The Medicare Part D PDP and MA plans must offer either
standard prescription drug coverage, as defined in the Act, or
"alternative prescription drug coverage with at least actuarially
equivalent benefits and access to negotiated prices."22
Actuarially equivalent plans (either through a PDP or MA) may
not have a higher deductible or higher out-of-pocket expenses
than the standard drug coverage plan. However, PDPs and
MAs may offer benefit designs with richer coverage (lower or no
deductible and lower or no monthly premium) than available
18. Pub. L. No. 108-173, 117 Stat. 2066. The MMA became effective on January
1, 2006. § 1860D-1(a)(2).
19. McArdle, supra note 2, at 1111.
20. 42 U.S.C.A. § 1395w-101(a)(1).
21. Id. Under the MMA, Part C has been renamed "Medicare Advantage."
§ 1395w-101(a)(3)(B).
22. § 1395w-102. Alternative prescription drug coverage must be approved by
the Secretary of Health and Human Services (Secretary). Id.
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under standard coverage.23
Moreover, effective January 1, 2006, Medicare beneficiaries
may no longer purchase new Medicare supplemental policies
that offer drug coverage.24 However, Medicare beneficiaries
with an existing supplemental insurance policy that includes
drug coverage may renew their policies after January 1, 2006,
provided they do not also select Medicare Part D coverage.25
The initial monthly premium for the Part D coverage, was
to average $35 per month increasing to an average $58 per
month in 2013, depending on plan choice. 26 Late enrollees who
select Medicare Part D after they are eligible for Parts A and B
are assessed a permanent one percent penalty added to their
monthly Part D premium for every month they are late in
enrolling in Part D.2 7 The deductible in 2006 was $250 per year,28
projected to increase to an average of $445 in 2013.29
The Part D cost sharing for enrollees is twenty-five percent
of drug costs that exceed the deductible up to the initial
coverage limit.30 The initial coverage limit was $2250 for 200631
and is estimated to be $4000 in 2013.32 Once the initial coverage
limit is reached, enrollees are responsible for drug expenses until
the stop-loss threshold is met.3 The stop-loss threshold in 2006
was $3600- and is projected to be $6400 in 2013.35 Once the stop-
loss threshold is met, beneficiaries are responsible for the greater
23. Id.
24. Id.
25. Id.
26. HENRY J. KAISER FAMRLY FOUNDATION, PRESCRIPTION DRUG COVERAGE FOR
MEDICARE BENEFICIARIES: A SUMMARY OF THE MEDICARE PRESCRIPTION DRUG,
IMPROVEMENT, AND MODERNIZATION ACT OF 2003 2 (2003),
http://www.kff.org/medicare/6112.cfm (last visited Nov. 4, 2004)
[hereinafter KFF PRESCRIPTION DRUG COVERAGE].
27. § 1395w-113(b).
28. § 1395w-102(b)(1)(A).
29. KFF PRESCRIPTION DRUG COVERAGE, supra note 26, at 3.
30. § 1395w-102(b)(2).
31. § 1395w-102(b)(3).
32. KFF PRESCRIPTION DRUG COVERAGE, supra note 26, at 3.
33. §§ 1395w-102(b)(3)-(4).
34. § 1395w-102(b)(4).
35. KFF PRESCRIPTION DRUG COVERAGE, supra note 26, at 3.
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of either five percent of the drug cost or a five-dollar co-pay for
brand name drugs and two-dollar co-pay for generic; Medicare
pays the remainder. 36 The federal government provides funding
for the Part D benefit through existing employer and beneficiary
subsidies, as well as through new subsidies (premiums, co-pays,
deductibles).3
The federal government subsidizes 74.5% of the Part D
expenses, which are provided by monthly premium subsidies
and reinsurance. 8  Annual deductibles and co-payments
provide the remaining 25.5%.39 Beginning in 2006, PDP and MA
plans receive an average of eighty percent of the expected
benefit costs from the federal government, and the remaining
twenty percent is provided by the monthly beneficiary
premiums and co-payments with additional adjustments in
future years.40
Additionally, the federal government provides annual
deductible and monthly premium subsidies for the low-income
Medicare population.41 The low-income population consists
primarily of dual-eligible beneficiaries, those who qualify for
both Medicare and Medicaid. 42 Beneficiaries with incomes
below 135% of the federal poverty line, and who meet an asset
test, are eligible to receive a full premium subsidy.43 All other
beneficiaries with incomes that fall beneath 150% of the federal
poverty line, and who also satisfy an asset test, receive premium
subsidies established by a sliding scale."4
The same poverty line criteria and asset test determine
whether the beneficiary is responsible for the annual
deductible. 5 Those "dual eligibles" with incomes below 135% of
36. § 1395w-102(b)(4).
37. § 1395w-115.
38. Id.
39. Id.
40. Id.
41. § 1395w-114.
42. Id.
43. § 1395w-114(a)(1).
44. § 1395w-114(a)(2).
45. § 1395w-114.
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the poverty line pay no deductible but have co-pays between
two dollars for generic and five dollars for brand-name
medication. 46 Other beneficiaries below 150% of the poverty line
pay a $50 deductible and have co-pays between two dollars for
generic medications and five dollars for brand-name
medications.47
The drug coverage under Medicare Part D, administered
through either a PDP or MA plan, may include all outpatient
prescription drugs approved under the individual states'
Medicaid programs.48 Medicare Part D does not include drugs
used in conjunction with an inpatient admission or as part of an
outpatient physician procedure, which have always been
covered under Parts A and B.49
PDP and MA plans may have formularies, so long as they
satisfy certain standards, including the development of
pharmacy and therapeutics (P&T) committees with appropriate
representation of physicians, pharmacists, and geriatricians.50
Moreover, PDP and MA plans must include at least two drugs
within each therapeutic class and category as defined by their
prescription drug plan.51 However, PDP and MA plans may
change drugs within categories and classes at the beginning of
each plan year.12 Enrollees must receive notice before a drug tier
status change creates a change in availability or a different co-
payment.13  Enrollees in a PDP or MA plan may appeal the
exclusion of a prescription drug from the plan's formulary only
if the prescribing physician determines that the existing
formulary drug would not be as effective for the treatment of the
illness or condition or would have an adverse health effect on
46. § 1395w-114(a)(1).
47. § 1395w-114(a)(2).
48. § 1395w-104.
49. § 1395w-102(e)(2)(B); FROLIK & BARNES, supra note 3, at 233.
50. § 1395w-104(b)(3)(A).
51. § 1395w-104(b)(3)(C).
52. Id. More frequent changes accommodate new drugs. Id.
53. § 1395w-104(b)(3)(E).
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the patient.M
Because PDPs and MAs may establish which drugs are
included on their formulary, they also may negotiate prices
directly and independently with drug manufacturers and
suppliers for all covered drugs.>5 Under the MMA, Medicare is
prohibited from negotiating any drug prices on behalf of any
PDP or MA. 66 Such negotiated drug prices for individual PDPs
and MAs no longer require the drug manufacturers' "best price"
requirements, as was required under the individual states'
Medicaid drug benefit programs.5 7
To maintain drug coverage under existing employee
retirement benefit plans, the federal government provides drug
subsidies to qualified retiree plans with a drug benefit, which is
"actuarially equivalent" to Medicare Part D basic coverage. 8
These subsidies are equivalent to twenty-eight percent of the
drug costs under the retiree program in excess of $250 per year,
up to a maximum of $5000 per year in 2006.51
ADDITIONAL MEDICARE REFORMS
The MMA also establishes a demonstration project for a
competitive Medicare delivery system, called the Comparative
Cost Adjustment Program (CCA), beginning in 2010.60 The CCA
will be a demonstration project linking fee-for-service Medicare
and private non-governmental Medicare health plans.6 1 The
CCA will be used to determine which delivery method (private
MA plans versus traditional fee-for-service Medicare) provides
better healthcare at lower cost.62
Moreover, beginning in 2006, the Secretary will establish
54. § 1395w-104(h).
55. § 1395w-102(d).
56. Id.
57. § 1395w-102(d)(1)(C).
58. § 1395w-132.
59. § 1395w-132(a)(3).
60. § 1395w-29.
61. Id.
62. Id.
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between ten and fifty regional MA plans.63 These MA plans are
to include not only a traditional fee-for-service Medicare and
HMO option but also PPO plans as defined in the legislation.M
Such regional MA plans are designed to mirror the current fee-
for-service Medicare Parts A and B and offer a single deductible
for both Parts A and B coverage as well as catastrophic and out-
of-pocket limits for Parts A and B.65
Additional changes to Medicare under the MMA include
modification of the Part B coverage benefit, deductible, and
premium. 66 Since its inception, Medicare Part B has covered
only "medically necessary" services.67  Under the MMA,
however, Medicare Part B covers some preventative care and
physicals as well as cardiovascular and diabetes screenings.68
Part B deductibles also increase from an average of $115 in 2006
to $166 in 2013.69 Part B premiums will be adjusted on an
income sliding scale beginning in 2007 for higher-income
beneficiaries. 70 Over five years, higher-income beneficiaries will
see the federal government's share of their premium subsidies
decrease from an average of sixty-five percent to fifty percent.71
The MMA also increases payments to MA HMO plans.72
Payments were increased beginning in 2004,73 and a new
payment methodology began in 2006.74 MA plan payments are
calculated based on regional benchmarks for each MA
geographic service area.75 Such payments are based according to
the plan's individual contract bid with the Secretary, which are
compared to regional MA plan benchmarks established by the
63. § 1395w-27.
64. Id.
65. § 1395w-27(b).
66. § 1395r.
67. FROLIK & BARNES, supra note 3, at 224.
68. § 1395x(s).
69. KFF PRESCRIPTION DRUG COVERAGE, supra note 26, at 10.
70. § 1395r(b).
71. § 1395r(i).
72. § 1395w-23.
73. Id.
74. Id.
75. Id.
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Secretary.76
POLITICS AND PASSAGE OF THE MMA
The Bush Administration's original drug program proposed that
Medicare offer drug coverage only to beneficiaries enrolled in
private Medicare Part C plans and no such coverage to seniors
who remained in the traditional fee-for-service components of
Medicare Parts A and B.7 However, after criticism from both
Republicans and Democrats, the administration abandoned the
idea of a different drug benefit depending on the beneficiary's
plan enrollment.78 The Bush Administration's original version
also included a provision "establishing a permanent national
system of direct competition between private plans and
traditional Medicare that many Republicans strongly favored
but Democrats detested."79
Drafting the bill created rifts in both parties; drug bill
proponents argued "it would expand Medicare and put it on a
firmer financial footing," but opponents argued "the private-
sector incentives went either too far or not far enough."80 The
initial bill passed by one vote on June 27, 2003, "only after a day
of arm-twisting" by Republican House Speaker Dennis Hastert,
Vice-President Dick Cheney, and Health and Human Services
Secretary Tommy Thompson. Senator John Kerry, expressing
views held by many congressmen, called the bill a "boondoggle
for the pharmaceutical industry." 82
Finally, at 6 a.m. on November 22, 2003, the final version of
the bill passed after the longest roll call (three hours) in House
76. Id.
77. John K. Iglehart, The New Medicare Prescription-Drug Benefit: A Pure Power
Play, 350 NEW ENG. J. MED. 826, 827 (2004).
78. Id.
79. Id. at 828.
80. Helen Dewar & Amy Goldstein, Medicare Bill Squeezes Through House at
Dawn, WASH. POST, Nov. 23, 2003, at A6.
81. Inglehart, supra note 77, at 827.
82. Id.
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history with 220 yeas and 215 nays.83 For more than an hour,
when the first vote was taken at 3 a.m., the bill stood at 218
against passage and 216 for passage, and Democrats believed
they had a victory." However, while the roll call stood open for
more than another hour, President Bush phoned Republicans,
ear-twisting them to vote in favor of the bill.8 5
On November 25, 2003, after only two days of debate, the
Senate approved the Medicare drug bill and sent it to President
Bush for his signature.86 Senator Edward M. Kennedy said the
House vote was "rigged," and he accused Republicans of trying
to "jam" the Senate by seeking a quick vote before their holiday
adjournment. 7  Despite the substantial costs added to the
Medicare program, "Republicans determined to break the long
hold that Democrats had maintained on Medicare as a political
asset seem to have achieved that goal by winning enactment of a
drug benefit.""
Originally, the Bush Administration estimated in its 2005
budget that the drug-benefit program would cost $530 billion
over its ten-year term.89 However, more recently, Congressional
Budget Office director Douglas Holtz-Easkin testified that the
program's costs "would exceed $1 trillion and could approach
$2 trillion" during the first decade of its existence.9o
WHO STANDS TO GAIN FROM MEDICARE PART D?
Widely considered to provide substantial financial benefit to the
health care industry, the passage of the MMA also benefits
senior advocacy group AARP.
83. Id. at 828.
84. Id.
85. Id.
86. Id. at 829.
87. Dewar & Goldstein, supra note 80, at A6.
88. Iglehart, supra note 77, at 832.
89. Id.
90. Id.
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PHARMACEUTICAL INDUSTRIES
In negotiations over the Medicare prescription drug plan,
no industry surpassed the pharmaceutical industry's lobbying
efforts to secure a favorable benefit design and defeat proposals
that would cut into their profits.91  For over a decade,
pharmaceutical and insurance companies blocked Congress
from adopting any sort of Medicare drug-benefit reform, even
though the AARP [American Association of Retired Persons]
and others advocating on behalf of seniors simply wanted
Congress to act.92
Finally, ten years after President Bill Clinton first proposed
prescription drug benefits for Medicare, interest groups became
aware that Congress was committed to changing Medicare,
changes that involved adding some sort of drug benefit.93 Before
passage of the MMA, Chip Kahn, president of the Federation of
American Hospitals, commented that "[t]here is a sense that
people are shooting with real bullets" this time.94 For many
pharmaceutical industry lobbyists, the stakes were simply too
big to ignore. Because the budget resolutions passed by the
House and Senate set aside $400 billion for Medicare reform,
various groups wanted a piece of the action, creating "a frenzy
of lobbying."95  Not surprisingly, drug companies and
manufacturers spent $78.1 million on lobbying and employed a
total of 623 different lobbyists in 2001.96 Since the 2000 elections,
the pharmaceutical industry contributed $60 million in political
91. Ceci Connolly, Drugmakers Protect Their Turf: Medicare Bill Represents Success
for Pharmaceutical Lobby, WASH. POST, Nov. 21, 2003, at A4 [hereinafter Drugmakers
Turf].
92. Jonathan Weisman, Prescription Bill Fuels Lobbying Blitz on Hill: Competition
Fierce for $400 Billion Pot, WASH. PosT, June 13, 2003, at A6.
93. Id.
94. Id.
95. Id.
96. Public Citizen, The Other Drug War II: Drug Companies Use an Army of 623
Lobbyists To Keep Profits Up, http://www.citizen.org/congress/reform/drug-
industry/contribution/articles.cfm?ID-7908 (last visited Nov. 6, 2006) [hereinafter
Other Drug War II].
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donations.97
PhRMA increased their lobbying expenditures from $7.5
million in 2000 to $11.3 million in 2001, spending more than any
other drug industry organization in 2001.98 PhRMA, however,
was not the only pharmaceutical organization sending lobbyists
to Capitol Hill. Pfizer employed eighty-two lobbyists; Bristol-
Myers Squibb, seventy-six lobbyists; and Eli Lilly and Amgen,
fifty-eight lobbyists.99  Individual pharmaceutical companies
also significantly increased their lobbying expenditures from
2000 to 2001: Glaxo SmithKline, a twenty-eight percent increase;
Eli Lilly, a twenty-three percent increase; Hofflam-LaRoche, a
twenty-three percent increase; and Johnson & Johnson, a
seventeen percent increase. 00  The lobbying efforts of the
pharmaceutical industry paid off handsomely. In 2001, although
overall profits of Fortune 500 companies dropped fifty-three
percent, the top ten drug companies increased profits thirty-
three percent from $28 billion in 2000 to $37.2 billion in 2001.1o1
Because of the passage of Medicare Part D, pharmaceutical
companies generated millions of new customers who previously
lacked prescription drug coverage. 102  Moreover, the
pharmaceutical industry defeated the reform measures they
feared most: legalized importation of lower-cost medicines,
governmental price controls, and easier market access for less
expensive generic drugs.10 3
The shift of 6.4 million people from state-administered
Medicaid programs to the new federal Medicare drug benefit
plan boosts the drug companies' annual revenues by as much as
two billion dollars.1s' Under Medicaid, drug companies are
97. Drugmakers Turf, supra note 91, at A4.
98. Other Drug War II, supra note 96.
99. Id.
100. Id.
101. Id.
102. Drugmakers Turf, supra note 91, at A4.
103. Id.
104. Tony Pugh, Drug Plan Means $2 Billion in Extra Profits: Companies Winners in
Medicare Program, SAN DIEGO UNION-TRIB., Jan. 3, 2006, at Al.
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required to charge their lowest or "best price" for medications
and prescriptions to those enrolled in state-administered
Medicaid programs.10 But under the MMA, pharmaceutical
companies need no longer pay states the drug rebates required
under the individual states' Medicaid program or offer private
drug plans the former Medicaid "best price." 06
By eliminating the "best price" provision under Medicare
Part D, pharmaceutical companies keep the discounts they
normally gave to the states under Medicaid. 07 "The net effect
over ten years is probably closer to $40 billion in extra profit,"
said Stephen Schondelmeyer, a pharmaceutical economics
professor at University of Minnesota. 0 Schondelmeyer studied
approximately forty Medicare plans in Minnesota and found
that the prices for the top twenty-five drugs are similar to retail
drug prices, but most plans' prices were twenty to thirty percent
higher than Medicaid prices.109 A pharmaceutical analyst at
Lehman Brothers agreed that Medicare will pay higher drug
prices than Medicaid and estimated a sales windfall of between
$1.8 billion and $2 billion for drug companies.1"0
HEALTH SERVICE COMPANIES AND HEALTH INSURERS
Another key lobbying group active in developing the
Medicare prescription drug bill was the health insurance and
health services industry."' Accounts of "strong-arm tactics to
push [the bill] through the House by pharmaceutical and
healthcare companies showering campaign gifts on key
lawmakers, and cozy arrangements for those who wrote the bill
and then departed for lucrative jobs as lobbyists" were
105. Id.
106. Id.
107. Id.
108. Id.
109. Id. at A12.
110. Id.
111. Dana Wilkie, Lobbying Ills Shine Through in Medicare Law: Watchdogs Say
Congress Caved, SAN DIEGO UNION-TRIB., Feb. 16, 2006, at A3.
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common.'1 2 According to the Center for Responsive Politics,
HMOs, health service companies, and health insurer "gave some
of their largest campaign gifts to lawmakers who wrote key
parts of the legislation, or who were leaders on committees
responsible for passing it.""1
Ten companies, including PacifiCare, collectively
contributed $6.5 million to congressional candidates over six
years, and these companies were granted federal contracts to
offer nationwide Medicare coverage.114  According to critics,
those nationwide contracts "ensure[] the profits of drug and
healthcare companies at the expense of the taxpayer.""'
The Medicare plans are administered by private health
insurers, which have taken a keen interest in the potential
profits.116 Cigna HealthCare views the Medicare drug program
as significant new business that is simply "too big to ignore." 17
According to Terri Swanson, vice president of senior products
for Cigna HealthCare, "[t]he 40 million or 42 million people
who've become eligible for Medicare Part D represent a very
large block of business, obviously, and so we saw that as a very
compelling reason to participate in Medicare Part D.""1s
The potential for new business, however, comes with the
risk of excessive drug costs, given that seniors tend to be high
consumers of prescription medications. Older Americans tend
to consume more prescription drugs and are not as profitable as
younger Medicare beneficiaries.119 Additionally, profits depend
on efforts to convince beneficiaries to change from brand-name
to generic drugs and the bargaining power of insurers.120
112. Id.
113. Id. at A17.
114. Id.
115. Id.
116. Morning Edition: Insurers Eye Potential Profits in New Medicare Program (NPR
radio broadcast Nov. 9, 2005) (transcript on file with MARQUETTE ELDER'S
ADVISOR).
117. Id.
118. Id.
119. Id.
120. Id.
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Despite these challenges, many insurance companies believe
they will have a profitable mix of enrollees by enrolling large
numbers of seniors. 121
Other healthcare experts, however, believe that the
traditional insurance model will not lead to profits from
Medicare Part D. According to Robert Laszewski, from Health
Policy and Strategy Associates, "[t]he basic principle of
insurance is that you get the sick people and the healthy people
coming together in the pool, and the healthy people paying for
premiums into the pool and offsetting the costs of the sicker
people." 122 Because the drug program is voluntary, Medicare
beneficiaries may not be signing up as quickly as the federal
government had originally budgeted.123 Therefore, insurers may
not have the premiums of healthy seniors to offset the cost of
sick seniors. Despite this risk, insurers can "take comfort from
the fact that if [their] profit calculations are wrong, the
government will protect them from large losses, at least for the
next two years."124
AMERICAN ASSOCIATION OF RETIRED PERSONS
The AARP's endorsement of the Medicare prescription drug
bill surprised many Democrats1 25 and likely led to the bill's
passage. The House and Senate minority leaders sent letters to
AARP chief executive William Novelli expressing their
"profound concern" and demanding an explanation from the
AARP for its decision, while other Democrats predicted that
Novelli would regret the AARP's endorsement.126 However,
according to the Bush Administration and the AARP, which
represents thirty-five million members age fifty and older, the
121. Id.
122. Id.
123. Id.
124. Id.
125. David S. Broder & Amy Goldstein, AARP Decision Followed a Long GOP
Courtship, WASH. POST, Nov. 20, 2003, at Al.
126. Id. at A14.
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AARP's endorsement was the product of mutual cultivation
over several years.127
The AARP's support for the bill, however, came at a price,
especially among its own membership. Only eighteen percent of
its members agreed with the organization's endorsement.128
Some AARP members protested outside the organization's
Washington, D.C., headquarters, tearing up their membership
cards. 129 Other members clogged the AARP's website and
bulletin board with angry messages.130
Why did the AARP endorse a drug program that only one
in five members supported? AARP officials acknowledged the
program was far from perfect, but assert it provided "the best
chance in years to begin offering badly needed help to seniors in
buying prescription drugs."131 Additionally, the AARP
indicated that Congress and the Bush Administration addressed
many of the AARP's concerns in exchange for its support.132
Such concessions included larger financial incentives to prevent
employer-sponsored retirement programs from dropping
benefits for retirees, additional financial assistance for low-
income Medicare beneficiaries, and a promise that the new
system of price competition from private health plans be an
experimental, rather than permanent, program."3
In contrast, some believe the AARP supports the drug
program to protect its own interests as an insurance entity.1'
The AARP softened its support of drug importation legislation
after announcing recent analysis that Medicare Part D could
save beneficiaries more money than prescriptions imported from
127. Id.
128. Id.
129. Id.
130. Id.
131. Id.
132. See id.
133. Id.
134. Henry J. Kaiser Family Foundation, AARP Analysis Finds Medicare Drug
Benefit Will Save Seniors More Money Than Prescription Drug Reimportation, Jan. 4,
2006, http://www.kaisemetwork.org/daily-reports/rep-index.cfm?hint-3&DRID-=
34589 (last visited Nov. 7, 2006).
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outside the U.S.135 Democratic Representative Sherrod Brown
commented, the "AARP is selling Medicare drug coverage, so
it's not surprising that they're pushing their own product."136
The AARP worked with UnitedHealth Group, a nationwide
health insurer which recently completed the acquisition of
PacifiCare Health Systems, to offer a joint AARP-UnitedHealth
Medicare drug plan, in which it already has more than two
million beneficiaries enrolled.137 Representative Brown further
alleged, "[njow [the AARP is] making an apples-to-oranges
comparison between Medicare drug coverage and Canadian
drug prices." 38
IS MEDICARE PART D DELIVERING WHAT WAS PROMISED?
States and some beneficiaries, particularly beneficiaries eligible
for both Medicare and Medicaid, cite unanticipated and
unwelcome costs. The Bush administration, however, asserts
the drug benefit is functioning as intended.
A STATE'S GAINS TURN INTO LOSSES
In 2006, the new Medicare prescription drug program was
expected to save California taxpayers an estimated $120 million
in drug costs for its Medicaid recipients.139 However, the state
had to allocate approximately $150 million for drug coverage for
low-income Californians.140 Although "dual eligibles" should
have been switched from Medicaid to Medicare Part D, this did
not occur because of various "bureaucratic foul-ups."141 In early
January 2006, California's Governor Arnold Schwarzenegger
signed a $70 million emergency relief bill to allow the state's one
135. Id.
136. Id.
137. Id.
138. Id.
139. Bill Ainsworth, "Double Whammy" Drug Program Turns Projected Savings to a
Loss, SAN DIEGO UNION-TRIB., Jan. 21, 2006, at Al.
140. Id.
141. Id.
144 [Vol. 8
MEDICARE PART D
million "dual eligibles" to purchase their prescriptions. 142
Additional costs related to the Medicare drug benefit may
be long-lasting. Assuming the implementation problems are
resolved, "it is projected to cost [California] an additional $59
million this fiscal year and more money in each subsequent year
because of flaws in the federal funding formula."14 3  State
officials project that by fiscal year 2008-09, "California will have
paid a total of $918 million more than if the program didn't
exist."144 Stan Rothstein, a deputy director for the California
Department of Health Services, argued the "state should be
getting 10 percent savings" because that is "what Congress said
when it passed the program and the president said when he
signed the bill."145  State assemblyman Dario Frommer
concluded the drug program is a "double whammy" because the
program is "seriously flawed" and costs more than the state's
Medicaid program.146
Moreover, some argue that the loss of one million "dual
eligibles" to the Medicare drug program will adversely affect
California's ability to negotiate reasonable drug prices for the
remaining six million Medicaid beneficiaries.147  Considering
these factors, some believe that both "California's budget and
low-income seniors and disabled [persons] would be better off
without Medicare Part D."'4s
MORE EXPENSES AND LESS COVERAGE
Of the forty-three million senior Americans eligible for the
new Medicare drug program, it is estimated that up to twelve
million of those beneficiaries with employer retirement benefits
could end up worse off if they do sign up for the Medicare drug
142. Cheryl Clark, Governor Offers $70 Million for Medicare Relief, SAN DIEGO
UNION-TRIB., Jan. 13, 2006, at Bl.
143. Ainsworth, supra note 139, at Al.
144. Id.
145. Id. at Al, A14.
146. Id. at A14.
147. Id.
148. Id.
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program or if their former employer drops prescription drug
coverage from its retirement plan.149 In the wake of Medicare
Part D, employers may continue their existing drug coverage, let
their retirees drop the drug coverage and keep the remaining
hospital and medical benefits, or end their drug coverage and
force their retirees into the Medicare drug program.5 o If
employers drop drug coverage, those retirees could face higher
out-of-pocket expenses for drugs.'5' However, a recent survey
shows that most employers are retaining their drug benefit.52
For Medicare beneficiaries who do not qualify for low-
income subsidies, monthly premiums, an annual deductible, and
coinsurance must be paid to obtain benefits under the Medicare
drug program.15 3 To qualify, beneficiaries must pay a monthly
premium of $35 and a $250 annual deductible, for the first
year.'TM  After meeting the deductible, beneficiaries are
responsible for twenty-five percent of drug expenses up to a
benefit limit of $2250 in 2006.15 For example, in 2006, seniors
spending $2250 on drugs will face a total out-of-pocket expense
of $1,170 under the Medicare drug program.'5 6  If the
beneficiary's drug costs exceed $2250 a year, there is no
additional benefit until total out-of-pocket drug expenses exceed
$3600.117 Medicare beneficiaries are completely responsible for
these drug costs until the $3600 threshold is met, and this
uncovered liability is referred to as the Medicare Part D
149. All Things Considered: New Medicare Drug Benefit Not a Boon to All (NPR
radio broadcast Dec. 9, 2005) (transcript available at http://www.npr.org/
templates/story/story/php?storyld=5046843 (last visited Nov. 4, 2006)).
150. Id.
151. Id.
152. Id.
153. Edward Walsh & Bill Brubaker, Drug Benefit's Impact Detailed: Many Will
Face Big Out-of-Pocket Costs, WASH. POST, Nov. 26, 2003, at A10.
154. Id.
155. Id. This initial coverage limit will increase to $4000 in 2013. KFF
PRESCRIPTION DRUG COVERAGE, supra note 26, at 3.
156. Walsh & Brubaker, supra note 153, at A10. ($35 x 12) + $250 + (0.25 x $2,000).
157. Id. This limit will increase to $6400 in 2013. KFF PRESCRIPTION DRUG
COVERAGE, supra note 26, at 3.
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"doughnut hole.""ss Thus, beneficiaries will be responsible for
an additional $1350, calculated as the $3600 less the $2250, in
out-of-pocket expenses. Once yearly drug expenses exceed
$3600, the program's "catastrophic drug coverage" provides
ninety-five percent coverage for drug expenses exceeding the
$3600.159 For example, a beneficiary with $6000 ($500 per month)
in drug expenses would be responsible for $2640 of those
expenses. 160
The Congressional Budget Office estimates 2006 average
drug spending by Medicare beneficiaries at $3245.161 At that
level of spending, a beneficiary's out-of-pocket expenses total
$2415, which includes the $250 deductible, twenty-five percent
coinsurance on the remaining $2000, monthly premiums of $420,
and $1245 to cover the entire cost of drugs exceeding the $2250
benefit limit.162 Consumer advocates estimate that 29.5 million
of 43 million total Medicare beneficiaries will reach or exceed the
$2250 benefit limit in 2006 if they elect to participate in the
Medicare drug program.163  Therefore, more than seventy
percent of Medicare beneficiaries in 2006 could have a
significant portion of their drug expenses fall into the "doughnut
hole."
FEWER BENEFITS FOR THE POOR
Twelve million low-income Medicare beneficiaries receive
Medicare drug program subsidies, in which premiums and
deductibles are significantly lower.'" Consumer advocates
argue, however, these beneficiaries will see a smaller benefit
under Medicare Part D than under Medicaid.165 Although these
low-income beneficiaries do not pay the standard Medicare
158. Walsh & Brubaker, supra note 153, at A10.
159. Id.
160. ($35 x 12) + $250 + (0.25 x $2000) + $1350 + (0.05 x $2400).
161. Walsh & Brubaker, supra note 153, at A10.
162. Id.
163. Id.
164. Id.
165. Id.
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prescription drug premium and deductible, they paid no
premiums or deductibles under Medicaid.16 6 Under Medicare,
low-income beneficiaries face higher co-pays than existed under
Medicaid. 167 Approximately one-half of the twelve million low-
income Medicare beneficiaries are dual eligibles under both
Medicare and Medicaid, and this population faces significant
challenges under the Medicare drug program.16
The Medicare drug program was intended to improve
access to prescription drugs, and to improve overall healthcare
for millions of senior Americans, but 7.2 million "dual eligibles"
have reduced benefits under the new program. 169 Before the
MMA, state Medicaid programs provided a low-cost and
comprehensive prescription drug program for "dual
eligibles."o70 Ten states required no co-payment, and others
required co-payments ranging from fifty cents to three dollars,
depending on whether the drug was generic or brand-name.171
Moreover, prior authorization was required for only a few select
"high-cost" drugs.172
Under Medicare Part D, even if the deductible and
premium are waived, dual-eligible beneficiaries will still be
responsible for a co-payment ranging from one to five dollars. 73
Moreover, research shows that policies implementing (even
minor) medication cost-sharing techniques reduce the use of
essential medications, which compromises patient health.174
Health advocates argue that the extension of drug benefits to
"dual eligibles" "was supposed to help the sickest of the sick -
the blind, disabled and low-income, many of them with
166. Cheryl Clark, New Medicare Law Trips Up the Poor: Doctors, Pharmacists Say
Some Will Die for Lack of Medicine, SAN DIEGO UNION-TRIB., Jan. 12, 2006, at Al.
167. Id. at A14.
168. Walsh & Brubaker, supra note 153, at A10.
169. Rachel A. Elliott et al., Benefits and Consequences for the Poor and the Disabled,
353 N. ENGL. J. MED. 2739, 2739 (2005).
170. Id.
171. Id. at 2740 tbl.
172. Id.
173. Id. at 2740.
174. Id. at 2741.
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behavioral or psychiatric diagnoses," and "[tlhese patients are
the least likely to fight for themselves." 75 "Dual eligibles" are
the poorest and sickest Medicare beneficiaries (eighty-three
percent report fair to poor health versus fifty-seven percent of
those not dually eligible). 7 6 Additionally, "dual eligibles" report
a higher rate of mental illness than those not dually eligible
(thirty-three percent versus twelve percent).'7
Transitioning "dual eligibles" to the Medicare drug
program raises several concerns. Because "dual eligibles" are
sicker and poorer than the general Medicare population, these
"high-risk" beneficiaries face problems transitioning coverage
and negotiating the Medicare system .17  Beneficiaries with
dementia or psychiatric illness (as many as 2.4 million people)
are particularly at risk for challenges moving from the state-run
Medicaid system and negotiating the prior-authorization system
for certain restricted medications under Medicare Part D.179
In California, "dual eligibles" encounter circumstances
similar to the rest of the nation's 7.2 million "dual eligibles."s 0
California has one of the highest populations of "dual eligibles,"
at more than one million, and San Diego County is home to
nearly 66,000.181 Many plans operating in California do not
cover basic prescription medications needed to treat glaucoma,
diabetes, high cholesterol, arthritis, and other common health
problems." 182  Maria Puig, a San Diego area doctor, said in
January 2006:
[B]y the end of the month, I'll be able to get you stories
of patients who drop dead in the streets because they
can't get their heart medication. And if they don't die,
they'll just get sick, go to the emergency room and be
175. Clark, supra note 166, at Al.
176. Elliott et al., supra note 169, at 2739.
177. Id. at 2739.
178. Id. at 2739.
179. Id. at 2740.
180. Clark, supra note 166, at Al.
181. Id.
182. Id. at A6.
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hospitalized. This is a total and complete disaster.83
Greg Knoll, a healthcare advocate, added, "[t]he patients are
in tears, and the pharmacy people are in tears."M Such alarming
accounts indicate that beneficiaries do not understand the new
Medicare drug program, and they may need to switch
medications if their new drug plan does not offer the same drugs
as their previous Medicaid drug plan.185 According to Knoll, this
is "one of the greatest public health disasters in our history in a
group that never had problems getting medicines before, but are
suddenly forced to choose between food and co-pays they
shouldn't have to pay."186
BUSH ADMINISTRATION SAYS PROGRAM WORKING
The Bush Administration's drug program was designed to
provide a comprehensive framework that would simultaneously
strengthen Medicare's guarantee to provide healthcare access to
all seniors while providing an affordable prescription drug
benefit to all of America's seniors.'87 Under the new Medicare
program, seniors have a choice of drug coverage, and no senior
will be forced into a governmental-administered prescription
drug plan. 88 By freeing up drug programs from federal
government bureaucracy, seniors have immediate access to
modem drugs currently available as well as new drug
treatments that are in the pipeline.89
According to the Department of Health and Human
Services, those countries with government-run prescription drug
programs do not guarantee seniors access to new, cutting edge,
183. Id.
184. Id.
185. Elliott et al., supra note 169, at 2740.
186. Clark, supra note 166, at A6.
187. White House of President George W. Bush, Fact Sheet: Framework To
Modernize and Improve Medicare, http://www.whitehouse.gov/news/releases/
2003/03/20030304-1.htnl (last visited Nov. 4, 2006) [hereinafter Framework].
188. Id.
189. Id.
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and potentially life-saving prescription drug therapie.1 90 In an
effort to control drug costs, coverage for new drugs in those
countries often is delayed while a government-appointed
committee decides which patients, if any, should have access to
the new drug.191 Moreover, such drugs often are restricted or
denied if they do not meet the government's criteria for
application and therefore are not included in the governmental
drug formulary.192  However, under the new Medicare
prescription drug program, competition allows seniors to select
from hundreds of drug plans to suit their own prescription drug
and budgetary needs.193
The Bush Administration says the new Medicare drug
program is doing exactly what it was designed to do: provide
seniors with wide access to affordable prescription drugs.194
Within ten weeks of Medicare Part D becoming effective,
"[m]ore than 26 million people have coverage, more than a
million prescriptions a day are being filled, and every week
hundreds of thousands more people are enrolling in the
program." 195 According to Dr. Mark McClellan, a Center for
Medicare and Medicaid Studies administrator, a survey released
in early March 2006 showed that "seniors overwhelmingly are
having no or little difficulty using their new coverage for the
first time."196 The survey found that once seniors connect with a
drug plan and utilize the prescription benefit, they typically save
fifty percent or more on their drug costs.197 Studies show that
seniors could save an additional twenty to thirty percent if they
190. White House of President George W. Bush, Strengthening Medicare:
Highlights of the New HHS Report, Securing the Benefits of Innovation for America's
Seniors, http://www.whitehouse.gov/infocus/rx-medicare/page3.html (last visited
Nov. 4, 2006).
191. Id.
192. Id.
193. Framework, supra note 187.
194. White House of President George W. Bush, Press Gaggle by Scott McClellan,
http://www.whitehouse.gov/news/releases/2006/03/20060314-5.html (last visited
Nov. 4, 2006) [hereinafter Press Gaggle].
195. Id.
196. Id.
197. Id.
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switch from brand-name to generic prescription drugs under
their plan, which creates a savings under Medicare Part D of as
much as eighty percent.198
Because of fierce competition between various drug plans,
seniors have access to drug programs that have filled the
"doughnut hole" coverage loss, thereby eliminating seniors'
financial exposure once their drug costs exceed the benefit limit
of $2250 per year.199 Seniors can enroll in drug plans that
provide a continuum of prescription drug coverage with no
additional financial exposure other than the monthly premium
and co-pay.200 Finally, the 2006 cost of the Medicare drug
program is about one-fifth lower than expected for taxpayers
and about one-third less for seniors. 20 1  Despite the White
House's admission to bumps and bruises in launching the
Medicare prescription drug program, the Administration says
such a benefit was needed for the forty-one-year-old universal
health insurance program for America's seniors.202
CONCLUDING FINDINGS AND RECOMMENDATIONS
An inventory of the program's considerable shortcomings may
yield useful amendments.
MEDICARE PART D SHORTCOMINGS
Little reliable information about the Medicare drug benefit
exists to make an accurate assessment of its overall performance
thus far. However, immediate opinions from both its
proponents and opponents are clear. Opponents argue that the
privatization of a Medicare drug benefit has led to pricing
inefficiencies, and the inability to allow drug importation,
198. Id.
199. White House of George W. Bush, Ask the White House,
http://www.whitehouse.gov/ask/20051117.html (last visited Nov. 4, 2006).
200. Id.
201. Press Gaggle, supra note 194.
202. Id.
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because of patents protecting such drugs, has created a captive
American drug market.20 3 Proponents point out that the plan is
working well; competition is driving prices down because of
contracts negotiated with drug manufacturers. 204
However, according to a recent report released by Public
Citizen, a national non-profit public-interest organization,
"[piroposals relying on private sector plans to offer prescription
drug coverage to Medicare beneficiaries would be vastly inferior
to a drug benefit offered directly by Medicare." 20 5 This report
found that Medicare HMOs offering drug coverage significantly
increased their premiums.20 6 The report found that Medicare
HMOs in fourteen states increased the average premium by
more than 100% from 1999 to 2003, and Medicare HMOs in eight
states increased premiums by more than 300%.207 Reportedly,
the biggest contributor to drug expense increases was the federal
government's inability to contract directly with drug
manufacturers. 208
The Democratic staff of the House Government Reform
Committee reported that drugs purchased under Medicare Part
D cost more than through other high volume programs.209 This
report stated that prescriptions purchased through the Medicare
prescription program are eighty percent higher than if
purchased through the Department of Veterans Affairs (VA),
sixty percent higher than if purchased through Canadian
pharmacies, and three percent higher than if purchased through
203. Andrew Harris, Recent Congressional Responses to Demands for Affordable
Pharmaceuticals, 16 LOY. CONSUMER L. REV. 219, 234 (2004).
204. Press Gaggle, supra note 194.
205. Public Citizen, Covering Medicare Prescription Drugs by HMOs and Insurance
Companies Would Be Unreliable and Costly, Study Shows, Sept. 26, 2002,
http://www.citizen.org/pressroom/release.cfm?ID=1227 (last visited Nov. 4, 2006).
206. Id.
207. Id.
208. Id.
209. Henry J. Kaiser Family Foundation, Daily Health Policy Report: Medicare
Prescription Drug Benefit Will Not Offer Prices as Low as Those Through VA, Canada,
Democratic Report Says; Medicare Officials Dispute Findings, Nov. 23, 2005,
http://www.kaisemetwork.org/daily-reports/rep_index.cfm?hint-3&DR_ID-33933
(last visited Nov. 4, 2006) [hereinafter Kaiser Daily Health].
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major U.S. pharmacies, such as Costco or Drugstore.com. 210 The
report also found that the main contributor to lower prices
through the VA and Medicare programs is the federal
government's negotiating power to leverage cost efficient
contracts, while the private sector (Costco and Drugstore.com)
cannot harness such deep discounts.211
Proponents of drug importation argue that such a ban
should be lifted under-the MMA, citing drugs from Canada are
safe and have saved Americans millions of dollars.212 For
example, before the MMA's drug importation ban, Springfield,
Connecticut, was the first city in the nation to sponsor such a
drug importation program for its city employees.213 Under the
importation program, Springfield's 3200 city workers opted to
have their prescriptions filled from a licensed Canadian
pharmacy that saved the city $2.5 million in the first year.214
Several other cities quickly followed Springfield's lead, ignoring
warnings from the Bush Administration that such drug
purchases made outside the U.S. were dangerous and illegal. 215
Feeling pressure from the lower-priced Canadian pharmacies,
drug manufacturers quickly responded by tightening sales to
Canadian pharmacies and warning that cities importing
Canadian drugs were exposing their citizens to the risk of
potentially harmful drugs from outside the U.S. 216
PROPOSED SOLUTIONS
Whether the issue concerning prescription drugs is price,
quality, patient safety, or consumer choice, the current Medicare
Part D prescription drug program under the MMA is in need of
refinement. Overall, the Medicare drug program is a step in the
210. Id.
211. Id.
212. Ceci Connolly, Drug Reimportation Plan Saves City $2.5 Million, WASH. POST,
July 15, 2004, at A3.
213. Id.
214. Id.
215. Id.
216. Id.
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right direction in providing access to much-needed prescription
drugs at reasonable prices that most seniors can now afford.
However, the current program has failed to consider the
population most at risk under the new Medicare drug program,
America's dual eligible seniors who are poor, disabled, or
mentally impaired.
Several steps should be taken to maximize the drug benefit
for the "dual eligibles" and to ease the switch from state
Medicaid drug programs to the new federal Medicare drug
program. There should be a longer transition period for those
"dual eligibles" whose medications were previously covered
under Medicaid and will not be covered under Medicare. 217 A
transition period of twelve months would allow the "dual
eligibles" to continue their current medications and slowly
transition to an equivalent drug covered under a Medicare MA
or PDP plan that the beneficiary chooses.218 This transition
period would include prescribing-education programs to
improve patient awareness of drug equivalent differences,
which would ensure patient safety and drug efficacy.219
Nonetheless, even if a long transition period is allowed for
those "dual eligibles," this population likely will discontinue
taking its medications if the Medicare drug program makes the
drugs themselves cost-prohibitive.2 20 In keeping with the spirit
of market-driven forces under the Medicare drug program,
individual states can maintain their existing MA or PDP plans
available for the general Medicare population but limit the plans
available for dual eligible beneficiaries. "Dual eligibles" can
select from a handful of PDP or MA plans that closely mirror the
individual state Medicaid program, including price, formulary,
and overall benefit design. These mirrored plans for "dual
eligibles" will ensure higher prescription drug compliance, less
confusion, and greater patient safety.
217. Elliott et al., supra note 169, at 2741.
218. Id.
219. Id.
220. Id. at 2740.
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The MMA's market-driven forces for the Part D drug
benefit also require reform. If the Bush Administration wants to
privatize senior healthcare, using market forces to drive down
and control drug costs, then the administration needs to remove
those obstacles that impede such competitive market forces.
Specifically, importation of drugs from Canada or Europe
should be allowed, if not encouraged. Provided that such
countries ensure drug safety and efficacy, which can be enforced
by the Food and Drug Administration before such drugs are
released into the U.S. marketplace, importation would
encourage competitive drug pricing and sales among U.S. drug
manufacturers. The current system of protectionism for
America's pharmaceutical industry under the MMA does
nothing more than continue price floors for domestic drug
manufacturers, who know they are shielded from competition.221
Finally, the current scheme of excluding the federal
government from bidding and negotiating directly with drug
manufacturers under the MMA leads to market inefficiencies.
There must be a direct, government-regulated pricing scheme,
similar to that used in Canada and Europe. Studies show that
the federal government leverages deeper drug discounts for
individuals with VA benefits than are possible for individual
private health insurers who negotiate independently with drug
manufacturers. 222 When the federal government represents and
negotiates drug benefits for all Medicare beneficiaries, drug
companies will offer competitive drug prices. Under the current
market-driven approach of the MMA, pharmaceutical
companies use "divide and conquer" methods to set prices with
individual health insurers as they see fit.
Congress's effort to fix America's prescription drug
problem with the MIVIA was an attempt to lower the
individual's cost for drugs. Unfortunately, the program was
designed with several flaws, and its goal of lower
pharmaceutical prices for America's seniors will not be fully
221. See Harris, supra note 203, at 234-35.
222. Kaiser Daily Health, supra note 209.
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realized. It was drafted with an eye toward interest groups, who
will be the true winners. Until Congress addresses the root
problem, the pharmaceutical companies' hold on drug prices
and importation market forces, America's Medicare beneficiaries
will be the losers.
S
